MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Merck & Co Inc.

Ouvert

SecteurSoins de santé

78.96 1.13

Résumé

Variation du prix de l'action

24h

Actuel

Min

77.77

Max

79.93

Chiffres clés

By Trading Economics

Revenu

583M

3.7B

Ventes

-1B

16B

P/E

Moyenne du Secteur

11.55

57.333

BPA

1.72

Rendement du dividende

4.15

Marge bénéficiaire

23.963

Employés

73,000

EBITDA

1.3B

6.9B

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+35.27% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.15%

2.63%

Date du Prochain Dividende

7 juil. 2025

Date du Prochain Détachement de Dividende

16 juin 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-56B

196B

Ouverture précédente

77.83

Clôture précédente

78.96

Score Technique

By Trading Central

Confiance

Bullish Evidence

Merck & Co Inc. Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 avr. 2025, 18:18 UTC

Principaux Mouvements du Marché

Pharma Shares Reverse Losses After Tariff Pause

9 avr. 2025, 09:39 UTC

Principaux Mouvements du Marché

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4 févr. 2025, 12:33 UTC

Résultats

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4 févr. 2025, 11:57 UTC

Résultats

Merck 4Q Sales Increase Results in Swing to Profit

24 avr. 2025, 20:08 UTC

Résultats

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 avr. 2025, 16:05 UTC

Actualités
Résultats

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

24 avr. 2025, 14:36 UTC

Market Talk
Résultats

Merck's Challenges with Gardasil in China Continue -- Market Talk

24 avr. 2025, 14:10 UTC

Market Talk
Résultats

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

24 avr. 2025, 11:35 UTC

Résultats

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

24 avr. 2025, 10:58 UTC

Actualités
Résultats

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

24 avr. 2025, 10:55 UTC

Résultats

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

24 avr. 2025, 10:31 UTC

Résultats

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

24 avr. 2025, 10:30 UTC

Résultats

Merck 1Q Keytruda Sales $7.21B >MRK

24 avr. 2025, 10:30 UTC

Résultats

Merck 1Q Pharmaceutical Sales $13.64B >MRK

24 avr. 2025, 10:30 UTC

Résultats

Merck 1Q Keytruda Sales Up 4% >MRK

24 avr. 2025, 10:30 UTC

Résultats

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

24 avr. 2025, 10:30 UTC

Résultats

Merck 1Q Pharmaceutical Sales Down 3% >MRK

24 avr. 2025, 10:30 UTC

Résultats

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

24 avr. 2025, 10:30 UTC

Résultats

Merck 1Q Januvia/Janumet Sales $796M >MRK

24 avr. 2025, 09:13 UTC

Actions en Tendance

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

24 mars 2025, 05:00 UTC

Résultats
Acquisitions, Fusions, Rachats

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5 mars 2025, 19:42 UTC

Actualités

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 mars 2025, 10:30 UTC

Actualités

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5 févr. 2025, 12:00 UTC

Actualités

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 févr. 2025, 14:48 UTC

Résultats

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4 févr. 2025, 11:51 UTC

Résultats

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4 févr. 2025, 11:50 UTC

Résultats

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4 févr. 2025, 11:31 UTC

Résultats

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4 févr. 2025, 11:31 UTC

Résultats

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4 févr. 2025, 11:31 UTC

Résultats

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

Comparaison

Variation de prix

Merck & Co Inc. prévision

Objectif de Prix

By TipRanks

35.27% hausse

Prévisions sur 12 Mois

Moyen 108 USD  35.27%

Haut 138 USD

Bas 85 USD

Basé sur 18 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

18 ratings

11

Achat

7

Maintien

0

Vente

Score Technique

By Trading Central

77.85 / 80.02Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Strong Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.